Bakhsh Hussain T
Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
J Microsc Ultrastruct. 2020 Dec 10;8(4):136-140. doi: 10.4103/JMAU.JMAU_54_20. eCollection 2020 Oct-Dec.
Hydroxychloroquine (HCQ) has been widely investigated for the treatment of COVID-19. Although it is rare, several case reports of acute toxicity of HCQ due to overdose have been reported during the last two decades. The aim of this review is to summarize the management options of acute HCQ toxicity.
A literature review that was conducted using an electronic search in the Google Scholar search engine. The inclusion criteria include any patient over 12 years old presenting with HCQ intoxication symptoms from January 1999 to January 2020.
Sixteen cases were found that have the inclusion criteria of this study. Most patients presented with altered mental status, electrocardiogram abnormalities, visual disturbance, and decrease cardiac output. Activated charcoal was the first line of management in nearly two-thirds of patients whereas 93.8% received fluid resuscitation and 81.3% of the patients need at least one type of vasopressor agent. Furthermore, potassium is given for 93.8% of the patient while 75% of the patients need sodium bicarbonate and intubation, lipid emulsion was used in three patients only and 13 patients survived.
The acute HCQ toxicity may result during the treatment period of COVID-19. The most common options can use in this situation include included gastric lavage and decontamination, IV fluid resuscitation, potassium replacement, sodium bicarbonate, intravenous lipid emulsion, and extracorporeal circulation membrane oxygenation. The role of diazepam is not clear but can be used in the significant toxicity while hyperkalemia associated with severe ingestions.
羟氯喹啉(HCQ)已被广泛研究用于治疗新型冠状病毒肺炎(COVID-19)。尽管罕见,但在过去二十年中已有数例因过量服用HCQ导致急性毒性的病例报告。本综述的目的是总结急性HCQ毒性的处理方法。
通过在谷歌学术搜索引擎中进行电子检索进行文献综述。纳入标准包括1999年1月至2020年1月期间出现HCQ中毒症状的任何12岁以上患者。
发现16例符合本研究纳入标准的病例。大多数患者出现精神状态改变、心电图异常、视觉障碍和心输出量降低。近三分之二的患者将活性炭作为一线处理措施,而93.8%的患者接受了液体复苏,81.3%的患者需要至少一种血管升压药。此外,93.8%的患者给予了钾,75%的患者需要碳酸氢钠和插管,仅3例患者使用了脂质乳剂,13例患者存活。
急性HCQ毒性可能在COVID-19治疗期间出现。这种情况下最常用的处理方法包括洗胃和去污、静脉液体复苏、补钾、碳酸氢钠、静脉注射脂质乳剂和体外膜肺氧合。地西泮的作用尚不清楚,但在严重毒性且伴有严重摄入相关的高钾血症时可使用。